Form 4: Karyopharm Therapeutics Executive Michael Mano Reports Stock and Option Awards

Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics, reports the acquisition of restricted stock units and stock options following a reverse stock split.

Summary

• On February 28, 2025, Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics Inc., was granted restricted stock units (RSUs) and stock options.
• The RSUs are granted pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended.
• 3,333 RSUs vest in three equal annual installments beginning February 28, 2026.
• 2,250 RSUs vest in two equal annual installments beginning February 28, 2026.
• He also acquired options to buy 6,666 shares at an exercise price of $7.95, vesting over 4 years.
• An additional option to buy 4,500 shares at an exercise price of $7.95 was also granted, vesting over 4 years.
• The reported amounts reflect a one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.
• Following these transactions, Mano directly owns 23,840 shares of common stock and options to buy 4,500 shares.
• The reporting was filed on March 4, 2025.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of equity awards, which is neutral in sentiment. The reverse stock split could be seen as slightly negative, but the equity awards are generally positive for incentivizing management.

Positives

• The grant of RSUs and stock options to a key executive suggests an incentive alignment with the company's long-term performance.
• The vesting schedules encourage continued service and contribution from the executive.

Future Outlook

The vesting schedules of the RSUs and stock options indicate a multi-year commitment from the executive.

Industry Context

Equity grants are a common practice in the pharmaceutical industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for executives in publicly traded biotechnology companies like Karyopharm Therapeutics.
• Companies such as Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans to align executive interests with shareholder value.
• The vesting schedules, typically ranging from 3 to 4 years, are consistent with industry norms to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of aligning management's interests with the company's performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates